NCT06087458View on ClinicalTrials.gov

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

March 31, 2028

Conditions
Age-Related Macular DegenerationGeographic AtrophyNon-neovascular AMD
Interventions
BIOLOGICAL

VOY-101

VOY-101

Trial Locations (11)

2000

ACTIVE_NOT_RECRUITING

Sydney Retina Clinic and Day Surgery, Sydney

3002

ACTIVE_NOT_RECRUITING

Cerulea Clinical Trials, East Melbourne

64239

RECRUITING

Tel-Aviv Sourasky Medical Center, Ophthalmology Division, Tel Aviv

76028

RECRUITING

Star Retina, Burleson

76092

RECRUITING

Retina Center of Texas, Southlake

84132

RECRUITING

University of Utah John A. Moran Eye Center, Salt Lake City

85255

RECRUITING

Retina Macula Institute of AZ, Scottsdale

91436

RECRUITING

The Retina Partners, Encino

92064

RECRUITING

Retina Consultants San Diego, San Diego

95825

RECRUITING

Retinal Consultants Medical Group, Sacramento

Unknown

RECRUITING

Rambam Medical Center, Haifa

Sponsors
All Listed Sponsors
lead

Perceive Biotherapeutics, Inc.

INDUSTRY

NCT06087458 - Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter